Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Bile Duct Neoplasms 3Stomach Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Venous Thromboembolism 1Supratentorial Neoplasms 1Solid Tumor 1Sigmoid Neoplasms 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Glioma 1Gallbladder Neoplasms 1Erectile Dysfunction 1Endometrial Neoplasms 1Dyskinesias 1Diarrhea 1Chemotherapy-Induced Febrile Neutropenia 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Long-Term Synaptic Depression × Clear all
NCT07187752 2025-09-23

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

Shandong Cancer Hospital and Institute

Phase NA Not yet recruiting
1,039 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡